
|Articles|June 1, 2003
PSA doubling of <3 months points to eventual death
Chicago-A post-treatment PSA doubling time less than 3 months followingeither surgery or radiation for localized or locally advanced prostate cancercan be a surrogate marker for eventual-perhaps inevitable-death from thedisease, according to data from a multicenter study of nearly 9,000 cancerpatients.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
2
Farah Rahman, MD, on monitoring resident wellness using biofeedback
3
Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS
4
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
5






